Trial Profile
A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Stem-cell-therapeutics-ExCellThera (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 06 Feb 2024 Planned End Date changed from 23 Sep 2025 to 17 Oct 2025.
- 08 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2022 Planned End Date changed from 1 Mar 2024 to 23 Sep 2025.